Special Issue

Molecular Mechanisms and Translational Research on Insulin Resistance

Message from the Guest Editor

Insulin resistance lies at the core of numerous metabolic diseases, including type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease, and cardiovascular diseases, amongst others. With the prevalence of metabolic disorders rising globally, we need to deepen our understanding of the biological mechanisms driving insulin resistance and translate this knowledge into effective clinical strategies. This Special Issue will showcase current advances in molecular research and translational approaches related to insulin resistance.

Authors are invited to submit original research articles, reviews, and clinical studies that address, but are not limited to, the following themes:

1. Disruptions in insulin signaling pathways and metabolic regulation;
2. The role of epigenetics and epitranscriptomics in insulin resistance;
3. The role of inflammatory pathways, oxidative stress, and mitochondrial dysfunction in insulin resistance;
4. Identifying and validating novel biomarkers for insulin resistance;
5. Emerging therapeutic interventions, including pharmacological approaches, for combatting insulin resistance.

Guest Editor

Dr. Terisha Ghazi

Department of Medical Biochemistry, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa

Deadline for manuscript submissions

31 January 2026

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/243749

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).